Get Involved

AD Genetics in Early Onset Alzheimer’s Disease

The AD Genetics – Early Onset Alzheimer’s Disease research study is for people with a diagnosis of Alzheimer’s disease before the age of 65.

Most cases of dementia develop by chance. The background causes of dementia are a mixture of environment, experiences, lifestyle and genetics.  Several genetic factors can influence the chances of someone getting Alzheimer’s disease – these are risk factors, not direct causes.

A few people with early onset Alzheimer’s have an inherited form of the disease. There are three genes where mutations cause early-onset Alzheimer’s disease. If one of these mutated genes is inherited from either parent, Alzheimer’s symptoms are likely to develop before age 65. The genes involved are:

  • Amyloid precursor protein (APP)
  • Presenilin 1 (PSEN1)
  • Presenilin 2 (PSEN2)

However, most people who have early-onset Alzheimer’s don’t have mutations in these three genes. It may be that there are more genetic risk factors still to be identified in early-onset Alzheimer’s disease.

Knowing what these genetic risk factors are will help drive new therapies

The AD Genetics – Early Onset Alzheimer’s Disease research study requires participation from people with Alzheimer’s disease who developed symptoms before the age of 65. The participants provide a blood sample, and have a short informal interview and a test of their mental function. The participant’s partner, carer or family member (who knows them well) is required to take part in an informal interview. Recruitment for this study is ongoing until 2020.

The findings of this study will improve understanding of the genetic, biological and environmental factors that cause early-onset Alzheimer’s disease. We expect that this will inform future research and lead to better treatments for Alzheimer’s disease.

Clinical Trials in Dementias and Neurodegeneration (DeNDRoN)

Select a trial from the list below to find out more about what it’s all about and how you can get involved in helping others.

ACDC

People who have Lewy body dementia, either Parkinson’s disease dementia or dementia with Lewy bodies, can have hallucinations. These hallucinations are often visual and may be disturbing for patients. The AC-DC study is the first treatment study aimed at reducing hallucinations.

Brains for Dementia Research

Brains for Dementia Research makes it easy for people to help research by donating brain tissue after death. Research using brain tissue from people who did not have dementia is important too.

AD Genetics in Early Onset Alzheimer’s Disease

The AD Genetics – Early Onset Alzheimer’s Disease research study is for people with a diagnosis of Alzheimer’s disease before the age of 65. Participants will be visited at a time and place convenient for them, usually in their own homes. The blood samples, interviews and memory tests take less than 2 hours. The participant’s partner, carer or family member will be interviewed at the same time.

SHAPED

Study of HAllucinations in Parkinson’s disease, Eye disease and Dementia

SUPErB

123I-MIBG Scintigraphy Utility as a biomarker for Prodromal Dementia with Lewy Bodies (SUPErB)

GAITDEM 20642

A study to assess the memory and walking of people

Investigating skin metabolites as a new way to diagnose Parkinson’s disease

This is a research study to investigate the chemicals known as metabolites found on the skin of people with Parkinson’s disease (PD).

Parkinson’s pen project (PPP): Developing a novel non-invasive aid for early diagnosis of Parkinson’s disease

Researchers at a number of universities across Europe (including Newcastle University) have developed a pen system (the Manus platform), which may help doctors to decide whether someone has Parkinson’s disease. Find out more here.


Latest news from PPI

View all